Literature DB >> 1376196

Benign prostatic hyperplasia. The scope of the problem.

J T Grayhack1.   

Abstract

BACKGROUND: The prevalence and incidence of clinical problems secondary to and associated with benign prostatic hyperplasia (BPH) are of increasing concern as the population ages.
METHODS: Selected published reports using anatomical and clinical criteria to identify BPH and its clinical sequelae were reviewed.
RESULTS: The following observations seem to reflect the current state of knowledge: (1) BPH develops with increasing frequency as men age; (2) BPH causes significant pathologic changes in the urinary tract of some patients and symptoms in others; and (3) other identifiable or cryptic etiologic factors may be the predominant cause of identical voiding dysfunction in patients with BPH.
CONCLUSION: Essential information about factors initiating and promoting development of BPH, the exact mechanisms by which BPH alters voiding mechanisms, and definitive diagnostic criteria to establish the role of BPH in clinical changes are lacking. Progress in these problem areas is essential to guide appropriate clinical management.

Entities:  

Mesh:

Year:  1992        PMID: 1376196     DOI: 10.1002/1097-0142(19920701)70:1+<275::aid-cncr2820701314>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Sexual Function and alpha-Blockers.

Authors:  Kevin T McVary
Journal:  Rev Urol       Date:  2005

2.  BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib.

Authors:  Feng Li; Laura E Pascal; Jianhua Zhou; Yibin Zhou; Ke Wang; Anil V Parwani; Rajiv Dhir; Peng Guo; Dalin He; Joel B Nelson; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2018-02-05

3.  The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables.

Authors:  G Haidinger; S Madersbacher; T Waldhoer; G Lunglmayr; C Vutuc
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

4.  Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia.

Authors:  Katherine J O'Malley; Kurtis Eisermann; Laura E Pascal; Anil V Parwani; Tsuyoshi Majima; Lara Graham; Katherine Hrebinko; Marie Acquafondata; Nicolas A Stewart; Joel B Nelson; Naoki Yoshimura; Zhou Wang
Journal:  Prostate       Date:  2014-04-07       Impact factor: 4.104

5.  Metabolic basis for contractile dysfunction following chronic partial bladder outlet obstruction in rabbits.

Authors:  D A Nigro; N Haugaard; A J Wein; R M Levin
Journal:  Mol Cell Biochem       Date:  1999-10       Impact factor: 3.396

6.  Differential impact of paired patient-derived BPH and normal adjacent stromal cells on benign prostatic epithelial cell growth in 3D culture.

Authors:  Wei Chen; Laura E Pascal; Ke Wang; Rajiv Dhir; Alexa M Sims; Robert Campbell; Gwenyth Gasper; Donald B DeFranco; Naoki Yoshimura; Zhou Wang
Journal:  Prostate       Date:  2020-07-13       Impact factor: 4.104

Review 7.  The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence.

Authors:  Kevin T McVary; Kevin E McKenna
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 2.862

Review 8.  Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man.

Authors:  Shane Russell; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 2.862

9.  Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches.

Authors:  Shao Li; Aiping Lu; Yongyan Wang
Journal:  Complement Ther Med       Date:  2009-12-02       Impact factor: 2.446

Review 10.  Medical therapy for benign prostatic hyperplasia progression.

Authors:  Kevin T McVary
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.